Open Access Open Access  Restricted Access Subscription Access

Drugs and Therapies for Cerebral Palsy: A Comprehensive Overview

Muralinath E., Pooja Devi, Prasanta Chbukdhara, Sanjib Borah, Kalyan C., Archana Jain, Guruprasad M.

Abstract


Cerebral palsy (CP) is a neurological disorder influencing coordination, movement and posture because of the damage or abnormal development of the brain. Muscle relaxant namely baclofen shows its action on the central nervous system (CNS) to decrease muscle spasticity, a common symptoms in CP. Baclofen increases inhibitory neurotransmitters, resulting in reduced Muscle tone. CP patients may feel seizures and anti convulsant namely phenobarbital and valproic acid stop convulsants and increase overall neurological stability. An injection of botulinum toxin injections namely Botox takes place into specific muscles to paralyze the muscles in a temporary manner and decrease spasticity and increase range of movement. Dopaminergic drugs (Levo dopa) can be administered to address movement issues particularly in CP. Levo dopa, a precursor to dopamine, is sometimes used to control motor symptoms as well as increase movement. Therapists use exercises and techniques to increase Muscle strength, coordination and mobility. Occupational therapists help individuals with CP in improving skills especially for daily living like dressing as well as feeding. For those with CP influencing speech as well as communication, speech therapy can show beneficial effect. Surgical procedures or orthopedic devices may be useful to address structural issues regarding CP. These interventions can assist regarding correction of joint functions as well as deformities and enhancement of overall mobility. Finally it is concluded that in managing CP, a combination of drug therapies and supportive interventions can enhance in a significant manner the quality of life for individuals affected by CP.


Full Text:

PDF

References


Baxter, P., Morris, C., Rosenbaum, P., Paneth, N., Leviton, A., Goldstein, M., ... & Brien, G. O. (2007). The definition and classification of cerebral palsy. Dev Med Child Neurol, 49(s109), 1-44.2.

Nelson, K. B. (2008). Causative factors in cerebral palsy. Clinical obstetrics and gynecology, 51(4), 749-762.

MacLennan, A. H., Thompson, S. C., & Gecz, J. (2015). Cerebral palsy: causes, pathways, and the role of genetic variants. American journal of obstetrics and gynecology, 213(6), 779-788.

McMichael, G., Bainbridge, M. N., Haan, E., Corbett, M., Gardner, A., Thompson, S., ... & MacLennan, A. H. (2015). Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy. Molecular psychiatry, 20(2), 176-182.

Van Eyk, C. L., Corbett, M. A., & Maclennan, A. H. (2018). The emerging genetic landscape of cerebral palsy. Handbook of clinical neurology, 147, 331-342.

Oskoui, M., Coutinho, F., Dykeman, J., Jetté, N., & Pringsheim, T. (2013). An update on the prevalence of cerebral palsy: a systematic review and meta‐analysis. Developmental Medicine & Child Neurology, 55(6), 509-519.

Morgan, C., Fahey, M., Roy, B., & Novak, I. (2018). Diagnosing cerebral palsy in full‐term infants. Journal of paediatrics and child health, 54(10), 1159-1164.

Whelan, M. A. (2004). Practice parameter: diagnostic assessment of the child with cerebral palsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 63(10), 1986-1986.

Graham, H. K., Rosenbaum, P., Paneth, N., Dan, B., Lin, J. P., Damiano, D. L., ... & Lieber, R. L. (2016). Cerebral palsy. Nature reviews Disease primers, 2(1), 1-25.

Novak, I., Morgan, C., Adde, L., Blackman, J., Boyd, R. N., Brunstrom-Hernandez, J., ... & Badawi, N. (2017). Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment. JAMA pediatrics, 171(9), 897-907.


Refbacks

  • There are currently no refbacks.